Loading...
Loading...
Thermo Fisher Scientific, Inc.
TMO reported 3Q2010 revenues/EPS of $2.68b/$0.90 that “beat our $2.61b/$0.81 estimates and consensus of $2.59b/$0.83,” Goldman Sachs reports.
Organic revenue growth of 4% exceeded expectations by 100bps and combined with solid margins to yield a clean beat for the quarter.
“We are revising our 2010-2012 estimates to $3.52/$3.96/$4.28 from $3.45/$3.86/$4.23 to reflect the strength in the Analytical Technologies division, higher FY2010 guidance, and updated F/X assumptions,” Goldman Sachs writes. “Our revised 12-month price target of $53 (previously $51) is based on our updated FY2011 estimates and unchanged multiples (P/E, EV/EBITDA).”
Thermo Fisher Scientific currently trades at $51.31.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In: Analyst RatingsGoldman SachsHealth CareLife Sciences Tools & Servicesthermo fisher scientific
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in